Skip to content

US · VIR · BIOTECHNOLOGY

Vir Biotechnology, Inc. (VIR) intrinsic value and stock valuation

$8.39as of 2026-11-21 · Mkt cap 1.54B

Data updated · price as of 2026-11-21

UndervaluedIC value is 20–50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Vir Biotechnology, Inc. DCF and intrinsic value

InvestorsCraft values VIR with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from VIR’s statements →

Vir Biotechnology, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Francisco, CA 94158 vir.bio

How the business is doing

Fiscal 2017–2025, USD

Revenue
$68.6M+0.4% 5y CAGRd
20172025
Net income
-$-437.99M
20172025
Free cash flow
-$-396.61M
20172025
Total equity
$765.3M+1.3% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$68.6M$74.2M$86.2M$1.62B$1.1B
Operating income-$-468.02M-$-587.16M-$-684.3M$833.1M$420.8M
Net income-$-437.99M-$-521.96M-$-615.06M$515.8M$528.6M
EPSd-$-3.16M-$-3.83M-$-4.59M$3.83M$3.96M
Operating cash flow-$-391.78M-$-446.35M-$-778.78M$1.66B-$-47.59M
Capital expenditure-$-4.83M-$-7.3M-$-21.57M-$-68.01M-$-21.82M
Free cash flow-$-396.61M-$-453.65M-$-800.36M$1.6B-$-69.41M
Total assets$1B$1.4B$1.92B$2.8B$1.95B
Total debt$186.9M$97.9M$124.5M$128M$137.5M
Net debt-$-47.2M-$-125.06M-$-117.04M-$-720.66M-$-210.33M
Total equity$765.3M$1.15B$1.59B$2.08B$1.43B
Cash and short-term investments$462.9M$905.4M$1.52B$2.4B$708.1M
Income statement
20252024202320222021
Revenue$68.6M$74.2M$86.2M$1.62B$1.1B
Cost of revenue$11.7M$478.6M$572.8M$621M$513.9M
Gross profit$56.9M-$-404.44M-$-486.65M$994.8M$581.5M
Research and development expenses$432.8M$506.5M$579.7M$474.7M$448M
Selling, general and administrative expenses$92.1M$0.00$0.00$0.00$0.00
Other expenses$0.00-$-323.77M-$-382.06M-$-312.89M-$-287.21M
Operating expenses$524.9M$182.7M$197.7M$161.8M$160.8M
Cost and expenses$536.6M$661.4M$770.5M$782.7M$674.7M
Interest income$40.2M$71.8M$87M$28.1M$440K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$11.7M$14.6M$19.5M$6.78M$5.81M
Ebitda-$-426.09M-$-508.91M-$-641.64M$761.1M$555.6M
Operating income-$-468.02M-$-587.16M-$-684.3M$833.1M$420.8M
Total other income/expenses, net$30.3M$64.1M$56.1M-$-78.79M$129.1M
Income before tax-$-437.77M-$-523.11M-$-628.19M$754.3M$549.8M
Income tax expense$220K-$-1.15M-$-13.08M$238.4M$21.2M
Net income-$-437.99M-$-521.96M-$-615.06M$515.8M$528.6M
Weighted average shares outstanding$138.5M$136.3M$134.1M$132.6M$129.9M
Weighted average diluted shares outstanding$138.5M$136.3M$134.1M$134.8M$133.4M
Balance sheet
20252024202320222021
Cash and short-term investments$462.9M$905.4M$1.52B$2.4B$708.1M
Net receivables$3.6M$0.00$0.00$0.00$773.1M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$514.1M$1.04B$1.59B$2.52B$1.56B
Property, plant and equipment, net$117.7M$122.9M$167.2M$188.2M$130.1M
Goodwill and intangible assets$24.8M$25M$39.5M$49.7M$50.2M
Long-term investments$314.6M$190M$105.3M$23.9M$201.4M
Total non-current assets$488.7M$356.3M$330.8M$283M$391.5M
Total assets$1B$1.4B$1.92B$2.8B$1.95B
Accounts payable$9.8M$5.08M$6.33M$6.42M$6.52M
Short-term debt$8.8M$7.75M$12.9M$4.14M$3.93M
Deferred revenue$0.00$12.7M$64.9M$15.5M$98.2M
Total current liabilities$92.8M$119.7M$175.4M$511M$341.2M
Long-term debt$178.1M$90.1M$111.7M$123.8M$133.6M
Deferred revenue, non-current$0.00$0.00$1.53M$53.2M$3.81M
Total non-current liabilities$144.7M$128.8M$153.4M$213.1M$181.2M
Capital lease obligations$89.1M$97.9M$124.5M$128M$137.5M
Total liabilities$237.6M$248.4M$328.8M$724.1M$522.4M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-1.2B-$-759.78M-$-237.82M$377.2M-$-138.6M
Accumulated other comprehensive income (loss)-$-2.06M-$-1.72M-$-810K-$-9.12M-$-1.1M
Total equity$765.3M$1.15B$1.59B$2.08B$1.43B
Total investments$543.3M$872.4M$1.39B$1.58B$561.7M
Total debt$186.9M$97.9M$124.5M$128M$137.5M
Net debt-$-47.2M-$-125.06M-$-117.04M-$-720.66M-$-210.33M
Cash flow statement
20252024202320222021
Net income-$-437.99M-$-521.96M-$-615.06M$515.8M$528.6M
Depreciation and amortization$21.2M$14.6M$19.5M$6.78M$5.81M
Stock-based compensation$49.1M$78.5M$0.00$102.1M$83.8M
Change in working capital-$-22.45M-$-84.01M-$-304.59M$665.4M-$-628.39M
Accounts receivable$0.00-$-6.51M-$-560K$770M-$-773.08M
Inventory$0.00$0.00$0.00$0.00$52.8M
Accounts payable$5M-$-990K$730K$800K-$-170K
Net cash provided by operating activities-$-391.78M-$-446.35M-$-778.78M$1.66B-$-47.59M
Investments in property, plant and equipment-$-4.83M-$-7.3M-$-21.57M-$-68.01M-$-21.82M
Acquisitions, net$250K$3.37M$100K$0.00$140.8M
Net cash used for investing activities$310.4M$499.4M$164.7M-$-1.19B-$-140.81M
Common stock issued$4.15M$4.55M$7.77M$28.5M$85.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$3.79M$4.39M$7.38M$34.8M$100.3M
Net change in cash-$-77.62M$57.4M-$-606.47M$504.6M-$-88.07M
Cash at end of period$241.1M$318.7M$254.8M$868M$363.4M
Operating cash flow-$-391.78M-$-446.35M-$-778.78M$1.66B-$-47.59M
Capital expenditure-$-4.83M-$-7.3M-$-21.57M-$-68.01M-$-21.82M
Free cash flow-$-396.61M-$-453.65M-$-800.36M$1.6B-$-69.41M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Vir Biotechnology, Inc.

        Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.

        CEO
        Marianne De Backer
        Employees
        367
        Beta
        1.62

        Explore

        Frequently asked questions

        What is the intrinsic value of Vir Biotechnology, Inc. (VIR)?

        Vir Biotechnology, Inc. (VIR) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is VIR undervalued?

        VIR trades at a price of $8.39 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.